Literature DB >> 22519822

Epigenetic mechanisms in commonly occurring cancers.

Lauren P Blair1, Qin Yan.   

Abstract

Cancer is a collection of very complex diseases that share many traits while differing in many ways as well. This makes a universal cure difficult to attain, and it highlights the importance of understanding each type of cancer at a molecular level. Although many strides have been made in identifying the genetic causes for some cancers, we now understand that simple changes in the primary DNA sequence cannot explain the many steps that are necessary to turn a normal cell into a rouge cancer cell. In recent years, some research has shifted to focusing on detailing epigenetic contributions to the development and progression of cancer. These changes occur apart from primary genomic sequences and include DNA methylation, histone modifications, and miRNA expression. Since these epigenetic modifications are reversible, drugs targeting epigenetic changes are becoming more common in clinical settings. Daily discoveries elucidating these complex epigenetic processes are leading to advances in the field of cancer research. These advances, however, come at a rapid and often overwhelming pace. This review specifically summarizes the main epigenetic mechanisms currently documented in solid tumors common in the United States and Europe.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22519822      PMCID: PMC3460614          DOI: 10.1089/dna.2012.1654

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  161 in total

1.  PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.

Authors:  Kenichi Yamane; Keisuke Tateishi; Robert J Klose; Jia Fang; Laura A Fabrizio; Hediye Erdjument-Bromage; Joyce Taylor-Papadimitriou; Paul Tempst; Yi Zhang
Journal:  Mol Cell       Date:  2007-03-15       Impact factor: 17.970

Review 2.  MicroRNAs: toward the clinic for breast cancer patients.

Authors:  Manuela Ferracin; Patrizia Querzoli; George A Calin; Massimo Negrini
Journal:  Semin Oncol       Date:  2011-12       Impact factor: 4.929

Review 3.  Current and potential anticancer drugs targeting members of the UHRF1 complex including epigenetic modifiers.

Authors:  Motoko Unoki
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-01       Impact factor: 4.169

4.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

5.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma.

Authors:  R J Weigel; E C deConinck
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

7.  The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation.

Authors:  Jing Wang; Sarah Hevi; Julia K Kurash; Hong Lei; Frédérique Gay; Jeffrey Bajko; Hui Su; Weitao Sun; Hua Chang; Guoliang Xu; François Gaudet; En Li; Taiping Chen
Journal:  Nat Genet       Date:  2008-12-21       Impact factor: 38.330

8.  Stool DNA and occult blood testing for screen detection of colorectal neoplasia.

Authors:  David A Ahlquist; Daniel J Sargent; Charles L Loprinzi; Theodore R Levin; Douglas K Rex; Dennis J Ahnen; Kandice Knigge; M Peter Lance; Lawrence J Burgart; Stanley R Hamilton; James E Allison; Michael J Lawson; Mary E Devens; Jonathan J Harrington; Shauna L Hillman
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

9.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

Authors:  Hirotaka Osada; Yoshio Tatematsu; Hiroko Saito; Yasushi Yatabe; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

Review 10.  Epigenetics in breast cancer: what's new?

Authors:  Yi Huang; Shweta Nayak; Rachel Jankowitz; Nancy E Davidson; Steffi Oesterreich
Journal:  Breast Cancer Res       Date:  2011-11-01       Impact factor: 6.466

View more
  12 in total

1.  The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Authors:  Stuart J Gallagher; Branka Mijatov; Dilini Gunatilake; Jessamy C Tiffen; Kavitha Gowrishankar; Lei Jin; Gulietta M Pupo; Carleen Cullinane; Rab K Prinjha; Nicholas Smithers; Grant A McArthur; Helen Rizos; Peter Hersey
Journal:  J Invest Dermatol       Date:  2014-06-06       Impact factor: 8.551

2.  Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation.

Authors:  Wesley L Cai; Jocelyn Fang-Yi Chen; Huacui Chen; Emily Wingrove; Sarah J Kurley; Lok Hei Chan; Meiling Zhang; Anna Arnal-Estape; Minghui Zhao; Amer Balabaki; Wenxue Li; Xufen Yu; Ethan D Krop; Yali Dou; Yansheng Liu; Jian Jin; Thomas F Westbrook; Don X Nguyen; Qin Yan
Journal:  Elife       Date:  2022-08-31       Impact factor: 8.713

3.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Authors:  Jian Cao; Zongzhi Liu; William K C Cheung; Minghui Zhao; Sophia Y Chen; Siew Wee Chan; Carmen J Booth; Don X Nguyen; Qin Yan
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

4.  Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes.

Authors:  Mike Ran Zou; Jian Cao; Zongzhi Liu; Sung Jin Huh; Kornelia Polyak; Qin Yan
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

5.  Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.

Authors:  Joyce Sayegh; Jian Cao; Mike Ran Zou; Alfonso Morales; Lauren P Blair; Michael Norcia; Denton Hoyer; Alan J Tackett; Jane S Merkel; Qin Yan
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

Review 6.  The roles of epigenetics in cancer progression and metastasis.

Authors:  Jocelyn F Chen; Qin Yan
Journal:  Biochem J       Date:  2021-09-17       Impact factor: 3.766

7.  CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.

Authors:  Meiling Zhang; Zongzhi Z Liu; Keisuke Aoshima; Wesley L Cai; Hongyin Sun; Tianrui Xu; Yangyi Zhang; Yongyan An; Jocelyn F Chen; Lok Hei Chan; Asako Aoshima; Sabine M Lang; Zhenwei Tang; Xuanlin Che; Yao Li; Sara J Rutter; Veerle Bossuyt; Xiang Chen; Jon S Morrow; Lajos Pusztai; David L Rimm; Mingzhu Yin; Qin Yan
Journal:  Sci Transl Med       Date:  2022-02-02       Impact factor: 19.319

Review 8.  Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies.

Authors:  Kira S Sheinerman; Samuil R Umansky
Journal:  Front Cell Neurosci       Date:  2013-09-10       Impact factor: 5.505

9.  Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study.

Authors:  Kira S Sheinerman; Vladimir G Tsivinsky; Samuil R Umansky
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

Review 10.  Researches of Epigenetic Epidemiology for Infections and Radiation as Carcinogen.

Authors:  Jong-Myon Bae
Journal:  J Prev Med Public Health       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.